SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES) today announced it is broadening its business model to include the development of a wider range of specialty pharmaceuticals targeting metabolic diseases. As part of the new strategy the Company will look to in-license preclinical and clinical compounds in these disease settings.
